DDInter649 DDInter782
Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line treatment of prostate cancer and remission can be achieved, arising resistance is inevitable, becoming castration-resistant prostate cancer. Until recently, docetaxel is the only treatment available for metastatic CRPC; however, AR inhibitors have been developed for more targeted therapy, although first-generation AR inhibitors like bicalutamide did not substantially increase the survival rate. Second-generation such as enzalutamide is more efficacious due to a higher affinity to AR and no partial agonist activity compared to bicalutamide.[A252667,A252642] Due to a favorable pharmacological profile,
In April 2018, the U.S. Food and Drug Administration (FDA) and the Swiss company Helsinn approved the intravenous formulation of AKYNZEO® (NEPA, a fixed antiemetic combination of fosnetupitant, 235mg, and palonosetron, 0.25mg) as an alternative treatment option for patients experiencing chemotherapy-induced nausea and vomiting . Fosnetupitant is the pro-drug form of netupitant [FDA label]. Generally, 25% to 30% of patients with a diagnosis of cancer receive chemotherapy as a treatment modality and 70% to 80% of these patients undergoing chemotherapy treatment may experience nausea and vomiting as major side effects. Considered one of the most distressing side effects of chemotherapy, nausea and vomiting has an immense impact on the quality of life of patients receiving certain antineoplastic therapies .
Enzalutamide {u} (Compound) resembles {v} (Compound) Nilutamide
Enzalutamide {u} (Compound) resembles {v} (Compound) Bicalutamide
Enzalutamide {u} (Compound) binds {v} (Gene) CYP3A4
Enzalutamide {u} (Compound) upregulates {v} (Gene) RPL39L
Enzalutamide {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 3A4 Inducers
Enzalutamide {u} (Compound) causes {v} (Side Effect) Musculoskeletal pain
Enzalutamide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Mirabegron
Enzalutamide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Relugolix
Enzalutamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Teriflunomide
Enzalutamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Remdesivir
Enzalutamide (Compound) resembles Nilutamide (Compound)
Enzalutamide (Compound) resembles Bicalutamide (Compound)
Enzalutamide (Compound) binds CYP3A4 (Gene)
Enzalutamide (Compound) upregulates RPL39L (Gene)
Enzalutamide (Compound) is included by Cytochrome P450 3A4 Inducers (Pharmacologic Class)
Enzalutamide (Compound) causes Musculoskeletal pain (Side Effect)
Enzalutamide may cause a minor interaction that can limit clinical effects when taken with Mirabegron
Enzalutamide may cause a minor interaction that can limit clinical effects when taken with Relugolix
Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Teriflunomide
Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir